Imane Khelif: IOC Reinstates SRY Tests, Transgender Women Excluded from 2028 Olympic Women’s Events

Imane Khelif remains unaffected as the International Olympic Committee approved Thursday (ET) a policy excluding transgender women from women’s Olympic events, to take effect at the Los Angeles Games in July 2028. The rule limits eligibility to biological women on the basis of a single SRY genetic screening test and is presented as protecting fairness and safety. The decision is not retroactive and will be implemented by international federations and national bodies through a one‑time chromosomal screening.

Key details of the new eligibility policy

The IOC published a 10‑page eligibility document that requires a single lifetime SRY test to qualify for female‑category competition and bars those who carry the SRY gene from women’s events. The policy also narrows participation among athletes with differences of sex development (DSD) and establishes that exemptions will be limited to those who can demonstrate total androgen insensitivity through complex, costly investigations. The new framework is positioned by the IOC as aligning with a U. S. presidential decree on female sport and is designed to be applied starting at the Los Angeles Games; it does not strip medals already awarded and therefore does not alter the Paris result for Imane Khelif.

Imane Khelif: immediate reactions and official language

Kirsty Coventry, president of the IOC, framed the change in stark competitive terms: “Even the smallest margins can make the difference between victory and defeat. It is therefore absolutely clear that it would be unfair for biological men to take part in women’s events, ” she said. The IOC’s text states, “Eligibility to any female event at the Olympic Games or any other IOC event is now limited to biological women, ” adding that the criterion rests on a single SRY genetic screening. The document notes that some athletes who are naturally carrying genetic variations will be excluded unless they can demonstrate an inability to use androgens, and it specifically references restrictions that will also affect athletes with DSD. The policy does not apply retroactively, preserving results such as the Paris medal won by Imane Khelif, and it reiterates that national and international federations will organise the required tests.

What’s next: implementation and likely challenges

Implementation will fall to international federations and national sport bodies, which must organise one‑time chromosomal testing and adjudicate complex medical claims. Practical and legal difficulties are flagged in the IOC document itself: genetic screening raises questions where domestic bioethics or privacy laws limit testing, and the IOC acknowledges that proving total androgen insensitivity requires expensive specialist work. The policy is expected to prompt legal challenges, medical reviews and intense federation-level rulemaking as the 2028 deadline approaches; athletes who have been subject to public scrutiny, such as Imane Khelif, will face new administrative processes even though past medals remain intact. Observers named in the IOC briefing warned of debates from scientists, jurists and human‑rights advocates as federations move from policy to practice, with close attention on how national laws will shape enforcement before July 2028 (ET).